AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

As the pharmaceutical industry undergoes a transformation with patent protection lapsing, investors are faced with the decision of which healthcare stocks to invest in moving forward - AbbVie Inc (NYSE:ABBV) or Pfizer Inc (NYSE:PFE). Both companies have established themselves as key players in the market, yet they differ greatly in their strategies and risk profiles.

AbbVie has successfully diversified its product portfolio beyond its historic blockbuster Humira, delving into high-growth therapeutic areas such as immunology, neuroscience, and aesthetics. In 2025, two of its key immunology drugs accounted for nearly 42% of the company's revenue. This diversification strategy allows AbbVie to mitigate some of the risks associated with relying heavily on a single blockbuster drug.

However, it also introduces a layer of customer concentration risk, as the company's sales are heavily reliant on a few major wholesalers like McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR).

On the other hand, Pfizer Inc has been aggressively deploying the capital it amassed during the pandemic era into new oncology and obesity treatments. As a cornerstone of many income-focused portfolios, Pfizer offers a different risk profile compared to AbbVie. While Pfizer's investment strategy may present a potentially higher reward, it also comes with a greater level of uncertainty due to the uncertainty surrounding the success of these newer treatments.

As investors navigate the shifting landscape of drug pricing reforms and evolving pipelines, they must carefully consider the distinct risk profiles of AbbVie and Pfizer. Each company presents unique opportunities and challenges, and the decision ultimately depends on the investor's risk tolerance and investment goals.